Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus paracasei 207-27
- Development stage
- Unknown
- Lead developer
- By-Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus paracasei 207-27 (also known as LPB27) is a probiotic bacterial strain originally isolated from healthy infant feces. It is being investigated for its immunomodulatory, anti-inflammatory, and neuroendocrine effects. Research suggests it may improve gut microbiota diversity, enhance intestinal barrier function, and modulate the gut-brain axis, potentially impacting sleep quality and stress response. Clinical studies, including those sponsored by BY-HEALTH and West China Second University Hospital, have evaluated its efficacy in managing infantile atopic dermatitis and improving sleep in adults under mild stress.
- Brand names
- LPB27LPB-27LPB 27
- Other names
- Lactobacillus paracasei 27Lacticaseibacillus paracasei 207-27LPB27LPB-27LPB 27
Beyond the preview
Go deeper on lacticaseibacillus paracasei 207-27.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus paracasei 207-27.